Navigation Links
UCLA engineer gets $4 million from Department of Energy to convert CO2 to liquid fuel using electricity
Date:5/21/2010

aid. "The immediate impact is that it solves the electricity storage problem by converting the electrical energy to liquid fuels that are fully compatible with the current infrastructure for distribution, storage and utilization."

In the long run, the process can be extended to utilize solar energy via electricity or electron mediators to directly produce liquid fuel usable in internal combustion engines.

Liao's grant was part of $106 million awarded under the American Recovery and Reinvestment Act to 37 research projects that focus on three critical areas: electrofuels (making biofuels from electricity), better batteries for electrical energy storage in transportation, and zero-carbon coal (innovative materials and processes for advanced carbon capture technologies).


'/>"/>

Contact: Wileen Wong Kromhout
wwkromhout@support.ucla.edu
310-206-0540
University of California - Los Angeles
Source:Eurekalert

Page: 1 2

Related biology news :

1. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
2. Innovative civil engineering application promises cleaner waters
3. Princeton engineers develop low-cost recipe for patterning microchips
4. UCR engineers to develop new tool to measure how environmental exposures affect health
5. UCI and CODA Genomics collaborate to re-engineer yeast for biofuel production
6. Boston University biomedical engineers find chink in bacterias armor
7. CU researcher engineers sorghum that grows in poisonous soils
8. A step toward tissue-engineered heart structures for children
9. Institution of Chemical Engineers chooses Elsevier as publishing partner
10. Green skies: Engineers work may reduce jet travels role in global warming
11. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... leaves, photosystem 1 (PS1) absorbs light and its ... carbon dioxide to biomass. Photovoltaic devices, mostly build ... but produce electricity. One approach for the development ... the semi-conductor with the isolated membrane protein complexes ... a highly stable PS1 from thermophilic cyanobacteria that ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
(Date:8/19/2014)... This news release is available in German . ... power are inherently intermittent energy sources. If a large amount ... in the future, excess energy will have to be stored ... for. However, existing storage capacities are far from adequate for ... better technologies. One important focus lies on battery systems that ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... A) today announced that its breakthrough Human Genome CGH ... Peter MacCallum Cancer Centre in a three-year study designed ... lining of the chest, the abdominal cavity and around ... Due to its active mining and manufacturing of asbestos ...
... The human fossil evidence from the Mladec Caves in Moravia, ... proven for the first time, through modern radiocarbon dating, to ... modern humans in Europe. , A team of researchers from ... Vienna in Austria and from the Washington University in St. ...
... Studying phage, a primitive class of virus that infects ... researchers have gained insight into the driving force behind ... in the past to occur through the release of ... all phages (also known as bacteriophages) are formed of ...
Cached Biology News:Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma 2Oldest cranial, dental and postcranial fossils of early modern European humans confirmed 2Basis for DNA ejection from single phage particles 2
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
(Date:8/19/2014)... 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the ... of its Oral Amphotericin B (Oral Amp B) ... conducted by ImmuneCarta®, the immune monitoring business unit ... of Oral Amp B in reactivating latent HIV ... intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... ... most complex toxicology study designs in South Korea , ... Cedar Knolls, NJ and Daejeon, South Korea (PRWEB) ... solutions and the developer of Pristima™ the premier preclinical solution on the market, is ...
... , , ABBOTT PARK, Ill., Aug. ... expansion of the company,s XIENCE V(R) USA post-approval study designed to ... Everolimus Eluting Coronary Stent System in a real-world clinical setting out ... from the XIENCE V USA trial to be eligible to cross ...
... , , , ... MON ) R&D pipeline is on the verge of a technology ... for growers and has the company poised to meet its goals ... and president, will tell investors today. , , ...
Cached Biology Technology:Korea Institute of Toxicology Implementing Xybion's Pristima™ 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 3Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 2Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 3Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 5Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 6Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 7
...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant canine ... culture supernates and serum.1 Each kit contains ... fifteen 96-well plates, provided that the following ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Component of HyperMu™ Insertion Kit...
Biology Products: